SecBot SecBot
8-K ·Filed Apr 20, 2026

PASG

Passage BIO, Inc.
MIXED
Impact 6/10
Horizonweeks Processed7mo ago SEC0001104659-26-045219
8-K context-dependent: Items 7.01
Actionable Insight ◆ Mixed

Monitor for updates on the strategic review process and any potential partnerships or transactions. The FDA's requirement for a randomized controlled trial presents significant challenges that could impact the development path and valuation of PBFT02.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$6.25
T+0 close · Apr 20, 2026 · via day close
Latest settled
−21.44%
T+60 · $4.91
Vs SPY
−28.22%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 20 $6.25entry
  2. T+1 · 7mo ago −1.12%α −0.47% · $6.18
  3. T+5 · 7mo ago −8.64%α −9.55% · $5.71
  4. T+20 · 6mo ago −18.08%α −22.28% · $5.12
  5. T+60 · 4mo ago −21.44%α −28.22% · $4.91
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Passage Bio disclosed updated interim data from its Phase 1/2 upliFT-D trial for PBFT02, showing reduced brain atrophy and stabilized plasma neurofilament levels in FTD-GRN patients. The FDA indicated a randomized controlled trial is required for registration, leading the company to evaluate strategic alternatives to maximize shareholder value.

Key Facts

  • PBFT02-treated patients with CDR score 1 showed 64% reduction in whole brain atrophy and 54% reduction in frontotemporal cortex atrophy compared to natural history
  • Plasma NfL levels among PBFT02-treated patients showed average reduction of 1.0 pg/mL at 12 months
  • FDA indicated a randomized controlled registrational study design is required for PBFT02 in FTD-GRN indication
  • Company has initiated a review of strategic alternatives including merger, acquisition, or sale of assets
  • Cash runway expected through 1Q 2027

Financial Impact

No direct financial impact disclosed, but strategic review could lead to significant changes in company direction or valuation

cash runwaystrategic direction

Risk Factors

  • FDA's requirement for randomized controlled trial presents ethical, logistical, and financial challenges
  • Strategic review may not result in any transaction

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-045219
Document: tm2612152d1_8k.htm0001104659-26-045219
Document: tm2612152d1_ex99-1.htm0001104659-26-045219
Document: 0001104659-26-045219-index-headers.html0001104659-26-045219
Document: 0001104659-26-045219-index.html0001104659-26-045219
Document: 0001104659-26-045219.txt0001104659-26-045219

Track record

15 reports on PASG

Performance horizon

2 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +22.24% at T+60 after the May 27, 2026 report. 4 of 7 went positive at some point.

Filters
  1. Nov 6, 202610d ago 8-K Neutral 5/10 Entry $3.98 Now $4.13 +3.90% settles Dec 7
  2. Oct 13, 20265w ago EFFECT Neutral 3/10 Entry $3.64 to $3.78 Now $4.13 +13.46% ▲ +3.85% +7.46% vs SPY
  3. Oct 8, 20265w ago S-4/A Bearish 6/10 Entry $3.69 to $3.98 Now $4.13 −11.92% ▼ −7.72% −13.28% vs SPY
  4. Oct 5, 20266w ago S-4/A Neutral 5/10 Entry $4.08 to $3.41 Now $4.13 +1.23% ▼ −16.47% −13.56% vs SPY
  5. Sep 21, 20268w ago S-4/A Neutral 5/10 Entry $4.95 to $3.60 Now $4.13 −16.57% ▼ −27.27% −26.71% vs SPY
  6. Sep 2, 202610w ago S-4/A / 425 Bearish 8/10 Entry $4.75 to $4.12 Now $4.13 +13.05% ▲ +13.26% +12.08% vs SPY
  7. Sep 2, 202610w ago 8-K Bullish 8/10 Entry $4.75 to $4.12 Now $4.13 −13.05% ▼ −13.26% −12.08% vs SPY
  8. Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
  9. Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
  10. Jun 24, 202620w ago 8-K Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 20, 2026